Chu Yuxin, Zhang Cheng, Xie Min
Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, United States.
The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, the State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital of Shandong University, Jinan, China.
Front Aging. 2021;2. doi: 10.3389/fragi.2021.681513. Epub 2021 Jun 8.
One of the characteristics of the failing human heart is a significant alteration in its energy metabolism. Recently, a ketone body, β-hydroxybutyrate (β-OHB) has been implicated in the failing heart's energy metabolism as an alternative "fuel source." Utilization of β-OHB in the failing heart increases, and this serves as a "fuel switch" that has been demonstrated to become an adaptive response to stress during the heart failure progression in both diabetic and non-diabetic patients. In addition to serving as an alternative "fuel," β-OHB represents a signaling molecule that acts as an endogenous histone deacetylase (HDAC) inhibitor. It can increase histone acetylation or lysine acetylation of other signaling molecules. β-OHB has been shown to decrease the production of reactive oxygen species and activate autophagy. Moreover, β-OHB works as an NLR family pyrin domain-containing protein 3 (Nlrp3) inflammasome inhibitor and reduces Nlrp3-mediated inflammatory responses. It has also been reported that β-OHB plays a role in transcriptional or post-translational regulations of various genes' expression. Increasing β-OHB levels prior to ischemia/reperfusion injury results in a reduced infarct size in rodents, likely due to the signaling function of β-OHB in addition to its role in providing energy. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have been shown to exert strong beneficial effects on the cardiovascular system. They are also capable of increasing the production of β-OHB, which may partially explain their clinical efficacy. Despite all of the beneficial effects of β-OHB, some studies have shown detrimental effects of long-term exposure to β-OHB. Furthermore, not all means of increasing β-OHB levels in the heart are equally effective in treating heart failure. The best timing and therapeutic strategies for the delivery of β-OHB to treat heart disease are unknown and yet to be determined. In this review, we focus on the crucial role of ketone bodies, particularly β-OHB, as both an energy source and a signaling molecule in the stressed heart and the overall therapeutic potential of this compound for cardiovascular diseases.
衰竭的人类心脏的特征之一是其能量代谢发生显著改变。最近,一种酮体,β-羟基丁酸酯(β-OHB),作为一种替代性“燃料来源”,被认为参与了衰竭心脏的能量代谢。β-OHB在衰竭心脏中的利用率增加,这作为一种“燃料转换”,已被证明在糖尿病和非糖尿病患者心力衰竭进展过程中成为对压力的适应性反应。除了作为替代性“燃料”外,β-OHB还是一种信号分子,可作为内源性组蛋白脱乙酰酶(HDAC)抑制剂。它可以增加组蛋白乙酰化或其他信号分子的赖氨酸乙酰化。β-OHB已被证明可减少活性氧的产生并激活自噬。此外,β-OHB作为含NLR家族pyrin结构域蛋白3(Nlrp3)炎性小体抑制剂,可减少Nlrp3介导的炎症反应。也有报道称,β-OHB在各种基因表达的转录或翻译后调控中发挥作用。在缺血/再灌注损伤前提高β-OHB水平可使啮齿动物的梗死面积减小,这可能是由于β-OHB除了提供能量的作用外还具有信号功能。钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂已被证明对心血管系统具有强大的有益作用。它们还能够增加β-OHB的产生,这可能部分解释了它们的临床疗效。尽管β-OHB具有所有这些有益作用,但一些研究表明长期暴露于β-OHB会产生有害影响。此外,并非所有增加心脏中β-OHB水平的方法在治疗心力衰竭方面都同样有效。将β-OHB用于治疗心脏病的最佳时机和治疗策略尚不清楚,有待确定。在本综述中,我们重点关注酮体,特别是β-OHB,作为应激心脏中的能量来源和信号分子的关键作用,以及该化合物对心血管疾病的整体治疗潜力。